Study RTOG 94-13: ADT and WPRT is nearing ten years. Results next year (Yeah).

New Topic Post Reply Printable Version
[ << Previous Thread | Next Thread >> ]

Tony Crispino
Veteran Member


Date Joined Dec 2006
Total Posts : 8128
   Posted 4/12/2008 6:25 PM (GMT -6)   
A very important study for advanced, locally advanced cases is nearing it's tenth year.
This study RTOG 94-13 has already acheived great results with patients that have exceeded 10 years.  Below is the study guidelines:
 
RTOG 94-13 (PROSTATE)
  • Title: A Phase III Trial Comparing Whole Pelvic Irradiation Followed by a Conedown Boost to Boost Irradiation Only and Comparing Neoadjuvant to Adjuvant Total Androgen Suppression (TAS)
  • Objectives:
    • (1) To test the hypothesis that TAS and whole pelvic irradiation followed by a conedown boost to the prostate improves the progression-free survival (an "early endpoint") by at least 10% at 5 years compared to TAS and prostate only irradiation.
    • (2) To test the hypothesis that induction (neoadjuvant) and concurrent TAS and RT, improves the progression-free survival (an "early endpoint") compared to adjuvant TAS and RT by at least 10% at 5 years. (10/13/95)
  • Protocol:
    • Arm 1: Neoadjuvant TAS 2 months before and during RT to the whole pelvis + prostate boost (70.2 Gy)
    • Arm 2: Neoadjuvant TAS 2 months before and during 70.2 Gy RT to prostate only (70.2 Gy)
    • Arm 3: RT to the whole pelvis + prostate boost (70.2 Gy) followed by 4 months of TAS
    • Arm 4: RT to the prostate only (70.2 Gy) followed by 4 months of TAS
  • Eligibility: Risk of LN involvement >15% based on pretreatment PSA and GS, N0M0; must not be eligible for RTOG 94-08
  • Enroll Target: 1200 patients
  • Activation: April 1, 1995
  • Closed: June 1, 1999

 

Related Information:

RTOG ~ Radiation Therapy Oncology Group... www.rtog.org

http://jco.ascopubs.org/cgi/content/full/21/10/1899 (Thanks Goody5)

 

Important note:

Stanford University enhanced this study by addressing post prostatectomy treatment including ADT and WPRT.  The criteria at Stanford was PSA >20, High Risk disease (Gleason 7>, and stage III).  The stanford results after five years showed more than twice as many patients in remission at year five.  The Stanford study is significant because IMRT was used.  RTOG was started and completed before IMRT.  IMRT allows higher concentration dosing in smaller areas.  There is no certanty that IGRT or Proton will share the same results results.  I'd like to see that result, but we'll have to wait quite some time. 

http://med.stanford.edu/profiles/radonc/frdActionServlet?choiceId=showPublication&pubid=237606&fid=4626

http://www.ncbi.nlm.nih.gov/pubmed/17459606?dopt=Abstract&otool=stanford

Post Edited (TC-LasVegas) : 4/12/2008 7:01:54 PM (GMT-6)


Swimom
Veteran Member


Date Joined Apr 2006
Total Posts : 1732
   Posted 4/12/2008 6:51 PM (GMT -6)   
Tony,

You are the research guru!!! Thanks for the information!

Swim
 


Tony Crispino
Veteran Member


Date Joined Dec 2006
Total Posts : 8128
   Posted 4/12/2008 6:54 PM (GMT -6)   
Thanks to Goody5 for motivating me to get the post out. I've been wanting to get it out but, procrastination is still a trait of mine.

Tony
Age 45 (44 when Dx)
Pre-op PSA was 19.8
Surgery on Feb 16, 2007
Post-Op Pathology: Gleason 4+3=7, positive margins, Stage pT3b (Stage III)
HT began in May, '07 with Lupron and Casodex 50mg
IMRT radiation for 38 Treatments ending August 3, '07
Current PSA (1/08): <0.1
I will continue HT until May '09. 
Years in Remission (3/23/07): 1
Visit my Journey at:
 
STAY POSITIVE!
 
Prostate Cancer Forum Moderator

New Topic Post Reply Printable Version
Forum Information
Currently it is Friday, June 22, 2018 1:33 AM (GMT -6)
There are a total of 2,974,368 posts in 326,171 threads.
View Active Threads


Who's Online
This forum has 161245 registered members. Please welcome our newest member, Girlwcurl.
141 Guest(s), 0 Registered Member(s) are currently online.  Details